Mega Contracts Monitor ($100M+) — February 24, 2026

$111M obligated ($54M outlayed) with $299M options to 2036 supports small-business biotech R&D under full competition.

$192M obligation since 2005 with $0 outlayed post-2020 end date highlights potential funding/execution failures in data services.

$0 outlayed on $192M obligation after 2020 end; no extensions noted

Options unexercised ($111M vs $299M); long horizon to 2036 dependent on BARDA continuity

Options exercise to unlock $299M total for Marburg immunotherapy R&D

Follow-on potential in CMS data processing given prior full/open competition win

HHS BARDA provides multi-year cost-plus-fixed-fee funding to small biotechs for virus therapies amid full competition.

Stalled $192M+ obligations in data hosting/services post-expiration underscore funding gaps.

{"entity"=>"MAPP Biopharmaceutical", "reason"=>"$111M active funding with expansion potential to $299M", "trigger"=>"Option exercises or outlay increases >$10M"}

{"entity"=>"QLARANT INTEGRITY SOLUTIONS LLC", "reason"=>"$192M stalled obligation flags follow-on need", "trigger"=>"New CMS awards or outlay activity"}

{"entity"=>"HHS BARDA Pipeline", "reason"=>"Pattern of large biotech R&D commitments", "trigger"=>"Additional $100M+ virus therapy contracts"}